- Home
- OTEX vs JAZZ Comparison
OTEX vs JAZZ Comparison
Compare OTEX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTEX
- JAZZ
- Stock Information
- Founded
- OTEX 1991
- JAZZ 2003
- Country
- OTEX Canada
- JAZZ Ireland
- Employees
- OTEX N/A
- JAZZ N/A
- Industry
- OTEX EDP Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- OTEX Technology
- JAZZ Health Care
- Exchange
- OTEX Nasdaq
- JAZZ Nasdaq
- Market Cap
- OTEX 6.6B
- JAZZ 6.1B
- IPO Year
- OTEX 1998
- JAZZ 2007
- Fundamental
- Price
- OTEX $27.14
- JAZZ $97.78
- Analyst Decision
- OTEX Hold
- JAZZ Strong Buy
- Analyst Count
- OTEX 8
- JAZZ 13
- Target Price
- OTEX $30.86
- JAZZ $181.85
- AVG Volume (30 Days)
- OTEX 1.2M
- JAZZ 1.3M
- Earning Date
- OTEX 04-30-2025
- JAZZ 05-06-2025
- Dividend Yield
- OTEX 3.87%
- JAZZ N/A
- EPS Growth
- OTEX 295.06
- JAZZ 49.21
- EPS
- OTEX 2.45
- JAZZ 7.51
- Revenue
- OTEX $5,220,017,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- OTEX N/A
- JAZZ $7.60
- Revenue Next Year
- OTEX $0.88
- JAZZ $3.47
- P/E Ratio
- OTEX $11.09
- JAZZ $13.02
- Revenue Growth
- OTEX N/A
- JAZZ 5.76
- 52 Week Low
- OTEX $22.79
- JAZZ $95.49
- 52 Week High
- OTEX $35.85
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- OTEX 57.61
- JAZZ 33.01
- Support Level
- OTEX $25.71
- JAZZ $97.50
- Resistance Level
- OTEX $27.67
- JAZZ $120.67
- Average True Range (ATR)
- OTEX 0.76
- JAZZ 4.33
- MACD
- OTEX 0.12
- JAZZ -0.53
- Stochastic Oscillator
- OTEX 66.02
- JAZZ 1.21
About OTEX Open Text Corporation
Open Text Corp is engaged in the design, development, marketing, and sale of Information Management software and solutions. Its software allows clients to archive, aggregate, retrieve, and search unstructured information (such as documents, e-mail, and presentations). Its platform and services provide secure and scalable solutions for enterprises, SMBs, governments, and consumers around the world. The company's solutions are marketed and delivered on the OpenText Cloud Platform, which is a comprehensive Information Management platform consisting of six business clouds; Content Cloud, Cybersecurity Cloud, Application Automation Cloud, Business Network Cloud, IT Operations Management Cloud, and Analytics Cloud. Geographically, it derives maximum revenue from the United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.